Portfoliotracker

BioInvent International AB (publ)

BINV.ST · STOCKHOLM · Healthcare Biotechnology 31/100 E

2,875 SEK
▲ +0,125 (+4,55 %)
Trading
Price as of 17. 11. 11:58, fetched 17. 11. 12:01
Next earnings–
Ex-dividend–
Analysts–
50 / 200 day average– / –

Price

Portfoliotracker score31 / 100 Market cap180 mil. SEK P/E– Forward P/E-0,7 P/S4,5 P/B0,9 EV/EBITDA– Dividend yield– FCF yield-250,86 % EPS-7,40 SEK Net margin0,0 % Return on equity-110,2 % Beta0,13 Debt / equity0,10
52-week range 1,90 to 34,75
3-month average volume0,4 M

Finance

Where the revenue goes

Loading the income statement flow…

Fundamentals

Loading key figures…

Insiders, analysts and people

All trades and changes

Loading insiders, analysts and opinions…

Co se právě děje

AI souhrn
Objednat AI souhrn, co se u firmy právě děje Vytvoří se jednou na pozadí a pak ho uvidí všichni. Ve verzi Free 3 objednávky měsíčně.

About the company

BioInvent International AB (publ), a clinical-stage company, discovers and develops immuno-modulatory antibodies for cancer therapy in Sweden, Europe, the United States, and internationally. The company's drug candidates include BI-1808, an anti- tumor necrosis factor receptor-2 (TNFR2) antibody in Phase 2a trial for the treatment of solid tumors and T-cell lymphoma; BI-1206, an anti-FcyRIIB antibody in Phase 2a trial for the treatment of non-Hodgkin's lymphoma, and solid tumors; BI-1910, an anti-TNFR2 antibody in Phase 1/2a clinical trial to treat solid tumors; BI-1607, an anti-FcyRIIB antibody in Phase 1b/2a clinical trial to treat solid tumors; and BT-001, an anti- cytotoxic T lymphocyte-associated protein-4 (CTLA-4) antibody in Phase 1/2a clinical trial for the treatment of solid tumors. It has a collaboration with Transgene oncolytic virus platform with BioInvent proprietary antibodies; MSD to evaluate BI-1808, BI-1910, BI-1206, BI-1607, and BT-001 in combination with Keytruda; CASI Pharmaceuticals to develop BI-1206 in both hematological and solid cancers; AstraZeneca to evaluate BI-1206 in combination with rituximab and Calquence; and XOMA. BioInvent International AB (publ) was incorporated in 1996 and is based in Lund, Sweden.

Employees
107
Country
Sweden
Data since
12. 6. 2001

Explore further

Similar companies HNSA.STSANION.STONCO.ST

Intraday chart

Your own portfolio, properties and finances in one place.

The account is free with no time limit. Only you see your data; nobody adds it up with others.

This is saved to your account. You can keep browsing, calculating and comparing without signing in.

Welcome back

Sign in and pick up where you left off.

or continue with

No account yet? Create a free account